HDV
Showing 1 - 25 of 96
Type 1 Diabetes Trial (HDV-Insulin Lispro)
Not yet recruiting
- Type 1 Diabetes
- HDV-Insulin Lispro
- (no location specified)
Jan 9, 2023
Bulevirtide Therapy in HDV Chronic Hepatitis in Italy
Completed
- Hepatitis D
-
Milan, MI, ItalyFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Divis
Jul 24, 2023
Viral Hepatitis D Relapses Upon Discontinuation of Bulevertide
Recruiting
- Chronic Hepatitis D
-
Moscow, Russian FederationCenter of Target Therapy
Nov 6, 2023
DELTA DESCRIBE: THE FRENCH COLLABORATIVE PROJECT
Recruiting
- Hepatitis D
- Patients co-infected HBV/HDV
-
Limoges, FranceChu Limoges
Jun 27, 2023
Burden of Hepatitis D Virus Infection in China Through
Not yet recruiting
- Hepatitis D
- +3 more
- HDV-Ab (IgG), HDV-RNA, RNA genotype
- (no location specified)
Nov 1, 2022
Patients With Hepatitis D Virus (HDV) Infection in China
Not yet recruiting
- Hepatitis D
-
Beijing, Beijing, ChinaBejing Tsinghua Changgung Hospital
Jul 7, 2022
Thailand HDV Cohort
Not yet recruiting
- HDV
-
Bangkok, Thailand
- +3 more
May 1, 2022
Hepatitis D Trial in Taipei (Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide)
Not yet recruiting
- Hepatitis D
- Ursodeoxycholic acid
- +2 more
-
Taipei, Taiwan
- +1 more
Jul 19, 2022
Bulevirtide in Patients With Chronic HBV/HDV Co-infection
Recruiting
- Hepatitis D, Chronic
- Hepatitis B, Chronic
-
Lyon, FranceZOULIM
Aug 5, 2021
A Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral
Completed
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
-
San Antonio, Texas(unnamed)
May 12, 2021
Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver Trial in Worldwide (REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated
Available
- Viral Hepatitis B
- +6 more
- REP 2139-Mg
- +2 more
-
Vienna, Austria
- +12 more
Feb 1, 2023
Burden of Hepatitis D Virus (HDV) Infection in Italy
Recruiting
- Chronic Hepatitis D
-
Bari, Italy
- +35 more
Feb 1, 2023
Diabetes Trial in United States (, Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15), Oral Hepatic Directed Vesicles
Completed
- Diabetes
- placebo
- +2 more
-
Muscle Shoals, Alabama
- +39 more
May 24, 2021
Hepatitis Delta Virus Trial in Worldwide (Peginterferon Lambda-1a)
Recruiting
- Hepatitis Delta Virus
- Peginterferon Lambda-1a
-
Los Angeles, California
- +61 more
Jan 30, 2023
Bulevirtide Therapy in Chronic Hepatitis Delta in Italy
Recruiting
- Hepatitis D
-
Milan, MI, ItalyFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Divis
Nov 7, 2023
Hepatitis D, Chronic Trial in Israel, New Zealand, Pakistan (Peginterferon Lambda-1A)
Completed
- Hepatitis D, Chronic
- Peginterferon Lambda-1A
-
Beersheba, Israel
- +3 more
Dec 20, 2022
Hepatitis D, Chronic Trial in Worldwide (JNJ-73763989, Placebo, Entecavir (ETV) monohydrate)
Active, not recruiting
- Hepatitis D, Chronic
- JNJ-73763989
- +4 more
-
Redwood City, California
- +68 more
Jan 17, 2023
Patient Knowledge, Beliefs and Barriers to Hepatitis D Care
Not yet recruiting
- Hepatitis, Delta
- Questionnaire based intervention
- (no location specified)
Aug 29, 2023
Disease Loads and Status of Treatment
Recruiting
- Chronic Hepatitis B
- +2 more
- Prospective serological assays
- Retrospective serological assays
-
Taipei City, TaiwanNational Taiwan University Hospital
Feb 28, 2022
Chronic Hepatitis b Trial in Lyon (procedure, biological, other)
Not yet recruiting
- Chronic Hepatitis b
- Investigation of the intrahepatic compartment using the fine needle aspiration (FNA) technique
- +2 more
-
Lyon, FranceHepatology Department - Hospices Civils de Lyon
Sep 14, 2023
Chronic Hepatitis B and Hepatitis D Co-infection Trial in Changchun (HH-003 20mg/kg, HH-003 3mg/kg)
Active, not recruiting
- Chronic Hepatitis B and Hepatitis D Co-infection
- HH-003 20mg/kg
- HH-003 3mg/kg
-
Changchun, Jilin, ChinaFirst Hospital of Jilin University
Dec 30, 2022
Safety and Biomarkers of Bulevirtide Treatment in Chronic
Recruiting
- Chronic Hepatitis D
-
Stockholm, SwedenKarolinska University Hospital, Department of Infectious Disease
Sep 27, 2023